WO2006111296A3 - Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem - Google Patents

Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem Download PDF

Info

Publication number
WO2006111296A3
WO2006111296A3 PCT/EP2006/003291 EP2006003291W WO2006111296A3 WO 2006111296 A3 WO2006111296 A3 WO 2006111296A3 EP 2006003291 W EP2006003291 W EP 2006003291W WO 2006111296 A3 WO2006111296 A3 WO 2006111296A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
immune system
biosynthesis inhibitors
additional effects
combined preparations
Prior art date
Application number
PCT/EP2006/003291
Other languages
English (en)
French (fr)
Other versions
WO2006111296A2 (de
Inventor
Juergen Lindner
Original Assignee
Juergen Lindner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juergen Lindner filed Critical Juergen Lindner
Publication of WO2006111296A2 publication Critical patent/WO2006111296A2/de
Publication of WO2006111296A3 publication Critical patent/WO2006111296A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft ein pharmazeutisches Präparat, enthaltend mindestens einen Pyrimidinsyntheseinhibitor wie Leflunomide, wobei der Pyrimidinsyntheseinhibitor nach oraler Applikation beim Menschen innerhalb von einer Stunde eine Blutplasmaspiegelerhöhung von 1,1 mg/Liter bis 5 mg/Liter erzeugt.
PCT/EP2006/003291 2005-04-16 2006-04-11 Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem WO2006111296A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005017592.9 2005-04-16
DE102005017592A DE102005017592A1 (de) 2005-04-16 2005-04-16 Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem

Publications (2)

Publication Number Publication Date
WO2006111296A2 WO2006111296A2 (de) 2006-10-26
WO2006111296A3 true WO2006111296A3 (de) 2007-04-19

Family

ID=36741320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/003291 WO2006111296A2 (de) 2005-04-16 2006-04-11 Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem

Country Status (2)

Country Link
DE (1) DE102005017592A1 (de)
WO (1) WO2006111296A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899746A1 (en) * 2013-01-31 2014-06-26 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising leflunomide
WO2014170435A2 (en) * 2013-04-18 2014-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for inhibiting lymphocyte proliferation in a subject in need thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0529500A1 (de) * 1991-08-22 1993-03-03 Hoechst Aktiengesellschaft Arzneimittel zur Behandlung von Abstossungsreaktionen bei Organverpflanzungen
EP0538783A1 (de) * 1991-10-23 1993-04-28 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
EP0551230A1 (de) * 1992-01-08 1993-07-14 Roussel Uclaf Cyano-2-Hydroxy-3-Enamid-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, diese enthaltende pharmazeutische Zusammensetzungen und erhaltene Zwischenprodukte
DE19857009A1 (de) * 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
WO2001043738A1 (de) * 1999-12-15 2001-06-21 Aventis Pharma Deutschland Gmbh Verfahren zur auffindung von nukleotidsyntheseinhibitoren mit weniger nebenwirkungen
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20020022646A1 (en) * 2000-02-15 2002-02-21 Ilya Avrutov Method for systhesizing leflunomide
US20020077485A1 (en) * 2000-08-14 2002-06-20 Ilya Avrutov Micronized leflunomide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0529500A1 (de) * 1991-08-22 1993-03-03 Hoechst Aktiengesellschaft Arzneimittel zur Behandlung von Abstossungsreaktionen bei Organverpflanzungen
EP0538783A1 (de) * 1991-10-23 1993-04-28 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
EP0551230A1 (de) * 1992-01-08 1993-07-14 Roussel Uclaf Cyano-2-Hydroxy-3-Enamid-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, diese enthaltende pharmazeutische Zusammensetzungen und erhaltene Zwischenprodukte
DE19857009A1 (de) * 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001043738A1 (de) * 1999-12-15 2001-06-21 Aventis Pharma Deutschland Gmbh Verfahren zur auffindung von nukleotidsyntheseinhibitoren mit weniger nebenwirkungen
US20020022646A1 (en) * 2000-02-15 2002-02-21 Ilya Avrutov Method for systhesizing leflunomide
US20020077485A1 (en) * 2000-08-14 2002-06-20 Ilya Avrutov Micronized leflunomide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRUSA PAOLA ET AL: "Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients", FARMACO (LAUSANNE), vol. 55, no. 4, April 2000 (2000-04-01), pages 270 - 275, XP002407623, ISSN: 0014-827X *
DATABASE SCISEARCH [online] SUGIOKA N (REPRINT) ET AL: "Protein binding study of mycophenolate mofetil, a new immunosuppressant, in human plasma and pharmacokinetics in renal transplant patients", XP002407627, retrieved from STN Database accession no. 1997:584713 *
DIMITROVA PETYA ET AL: "Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation", JOURNAL OF IMMUNOLOGY, vol. 169, no. 6, 15 September 2002 (2002-09-15), pages 3392 - 3399, XP002407624, ISSN: 0022-1767 *
JAPANESE JOURNAL OF TRANSPLANTATION, VOL. 32, NO. 1, PP. 33-42. ISSN: 0578-7947. PB - JAPANESE SOC TRANSPLANTATION, C/O DR KIKUO NOMOTO, NIHON GAKKAI JIMU CENTER, 5-16-9 HONKOMAGOME, BUNKYO-KU, TOKYO 131, JAPAN., 1997 *
LI JUN ET AL: "Pharmacokinetics of leflunomide in Chinese healthy volunteers", ACTA PHARMACOLOGICA SINICA, vol. 23, no. 6, June 2002 (2002-06-01), pages 551 - 555, XP002407622, ISSN: 1671-4083 *

Also Published As

Publication number Publication date
DE102005017592A1 (de) 2006-10-19
WO2006111296A2 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2005097076A3 (en) Low dose pharmaceutical products
WO2006044805A3 (en) Less abusable pharmaceutical preparations
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
WO2007068934A3 (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2008045266A3 (en) Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2004074266A8 (en) Hiv inhibiting 1,2,4-triazines
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
RS20060662A (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004041189A3 (en) A method for inhibiting cancer development by fatty acid synthase inhibitors
WO2003068157A3 (en) Kinase inhibitors and methods of use thereof
WO2006111296A3 (de) Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06724220

Country of ref document: EP

Kind code of ref document: A2